Maxtra is a combination medicine used to relieve the symptoms of cold associated with fever; these may include nasal congestion, excess production of mucus, runny nose, etc.
Phenylephrine Belongs to the class of topical sympathomimetic agents used as nasal decongestants, ophthalmologic decongestants and used in the treatment of heart failure.
Maxtra is product of Emcure Pharmaceuticals. Emcure, headquartered at Pune in West India, is an Indian pharmaceutical company. The company’s products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
Nasal congestion or “stuffy nose” occurs when nasal and adjacent tissues and blood vessels become swollen with excess fluid, causing a “stuffy” plugged feeling. Nasal congestion may or may not include a nasal discharge or “runny nose.”
Nasal congestion usually is just an annoyance for older children and adults. But nasal congestion can be serious for children whose sleep is disturbed by their nasal congestion, or for infants, who might have a hard time feeding as a result.
Patient with CV disease (e.g. ischaemic heart disease, pre-existing bradycardia, partial heart block, severe coronary artery disease, heart failure, cardiogenic shock), diabetes mellitus, asthma, arteriosclerosis, aneurysm, hypertension, narrow-angle glaucoma. Renal impairment (IV). Children. Elderly. Pregnancy (especially those with history of pre-eclampsia) and lactation. Patient Counselling Eye drops may cause temporary blurring of vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure.
Severe hypertension, ventricular tachycardia, severe hyperthyroidism. Ophthalmic (10% solution): Close-angle glaucoma. Children and elderly. Cold preparations should not be used in children <2 years. Concomitant or within 14 days of MAOI use (oral).
Concomitant use with adrenergic blocking agents (e.g. phentolamine), phenothiazine drugs (e.g. chlorpromazine) and amiodarone may cause antagonistic effects. May potentiate pressor effects of oxytocic drugs and CV depressant effects of inhalational anaesthetics (e.g. cyclopropane, halothane). May increase risk of arrythmias with cardiac glycosides and quinidine. May enhance the effects of anticholinergic drugs (e.g. TCAs).
Potentially Fatal: Concomitant use with MAOIs (or within 14 days of stopping MAOIs) may result in paroxysmal hypertension and fatal hyperthermia.
Symptoms: Headache, nausea, vomiting, paranoid psychosis, hallucinations, seizures, cerebral haemorrhage, palpitation, paraesthesia, reflex bradycardia, cardiac arrhythmia (e.g. ventricular tachycardia and extrasystoles), sensation of fullness in the head and tingling of extremities. Management: Symptomatic and supportive treatment. α-adrenergic blockers (e.g. phentolamine) may be used to treat severe hypertension.
Mechanism of Action
Phenylephrine is a sympathomimetic amine that has direct effect on α-adrenergic receptors and an indirect effect of releasing norepinephrine from its storage sites. Its main effect is systemic arterial vasoconstriction. Additionally, it produces local vasoconstriction on dilated arterioles of the conjunctiva and nasal mucosa.